Who is sponsoring NCT07314814?

NCT07314814 is sponsored by Prof. Valérie Mc Lin.

What drugs are being tested in NCT07314814?

Interventions in NCT07314814: targeted gene panels analysis, whole genome analysis.

What condition does NCT07314814 study?

NCT07314814 studies Portopulmonary Hypertension, Pulmonary Arterial Hypertension (PAH), Congenital Portosystemic Shunt.

Is NCT07314814 still recruiting?

NCT07314814 is currently not yet recruiting. Last updated 20 January 2026.

Last reviewed 2026-01-20 · How we verify

NCT07314814: Gen-PoPH-CPSS

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Genetic Hallmarks of Patients With Congenital Portosystemic Shunts and Portopulmonary Hypertension

Not yet recruiting Last updated 20 January 2026

What this trial tests

trial testing targeted gene panels analysis in Portopulmonary Hypertension in 120 participants. Not yet recruiting.

Timeline

1 February 2026

Primary endpoint
31 August 2029

31 January 2030

Quick facts

Lead sponsor	Prof. Valérie Mc Lin
Status	Not yet recruiting
Study type	OBSERVATIONAL
Enrollment	120
Start date	1 February 2026
Primary completion	31 August 2029
Estimated completion	31 January 2030
Sites	1 location across Switzerland

Drugs / interventions tested

targeted gene panels analysis
whole genome analysis

Conditions studied

Portopulmonary Hypertension — all drugs for Portopulmonary Hypertension →
Pulmonary Arterial Hypertension (PAH) — all drugs for Pulmonary Arterial Hypertension (PAH) →
Congenital Portosystemic Shunt — all drugs for Congenital Portosystemic Shunt →

Sponsor

Prof. Valérie Mc Lin

Who can join

Adults 1 Day to 99, any sex, with Portopulmonary Hypertension or Pulmonary Arterial Hypertension (PAH). Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Congenital portosystemic shunt (CPSS) are rare vascular malformations causing blood from the intestines to bypass the liver and directly flow into body's general circulation. Such liver bypass can cause several health problems, one of the most severe being portopulmonary hypertension (PoPH). The goal of this study is to identify pathogenic and potentially pathogenic genetic variants in patients who have both CPSS and PoPH. Future research will assess the contribution of these genetic variants to the development of PoPH. The long-term goal is to use genetic information to identify patients with congenital portosystemic shunts (CPSS) or chronic liver disease who are at risk of developing PoPH to offer anticipatory management. Children and adult patients with both CPSS and PoPH, as well as their close relatives (patient's parents and siblings) can take part in the study. Genetic variations within each family will be studied.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other Prof. Valérie Mc Lin trials

Trials by the same sponsor.

NCT06041906 — International Registry of Congenital Portosystemic Shunt (IRCPSS) · enrolling by invitation

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT07314814 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Prof. Valérie Mc Lin
Last refreshed: 20 January 2026

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT07314814.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing